Biotts develops proprietary drug delivery technologies that enhance the bioavailability and absorption of diabetes medications through specialized formulations. Their solutions improve patient adherence and clinical outcomes by providing more effective and user-friendly delivery systems for diabetes management.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional drug delivery methods, such as oral pills and injections, often result in variable drug levels, reduced bioavailability, and increased side effects due to the drug's metabolism in the body. Transdermal drug delivery is limited by the skin's impermeability to large molecules, restricting the range of drugs that can be administered effectively through this route.
Solution
Biotts is a biotech company specializing in transdermal drug delivery systems using its proprietary Multifunctional Transdermal Carrier Y (MTC-Y™) technology. This semi-solid emulsion facilitates the transport of both lipophilic and hydrophilic molecules, including peptides and proteins up to 6,000 Da, through the skin and into the bloodstream. MTC-Y™ allows drugs to quickly penetrate the skin without irritation, offering a less invasive alternative to injections with a more constant drug level. The technology improves drug bioavailability, reduces administration frequency, and enhances self-administration, leading to improved patient outcomes and quality of life. Biotts develops its own transdermal drug products and collaborates with the pharmaceutical industry to make its technology available for a wider range of active ingredients.
Target Audience
The primary target audience includes pharmaceutical companies seeking to improve drug delivery methods, as well as patients requiring effective, non-invasive alternatives to traditional oral and injectable medications.
Features
- MTC-Y™ carrier system enables transdermal delivery of molecules up to 6,000 Da, including peptides and proteins.
- Semisolid emulsion formulation ensures rapid drug penetration without skin irritation.
- Enhanced bioavailability compared to oral administration, leading to more effective drug delivery.
- Sustained and controlled drug release profile for consistent therapeutic effects.
- Potential for reduced side effects compared to traditional drug delivery methods.
- Capability to transport multiple active substances for designing multi-component drugs.
- Applicability to various therapeutic areas, including oncology, diabetology, and pain management.
- Patented technology with secured patents in the U.S. and Japan.